Business Wire08.29.18
SpinalCyte LLC, a regenerative medicine company focused on regrowth of the spinal disc using Human Dermal Fibroblasts, has been issued U.S. Patent No. 10,052,410, “Methods and Compositions For Repair Of Cartilage Using An In Vivo Bioreactor.”
The technology described in the patent involves an in vivo bioreactor that acts as a delivery system to feed and grow cells, like fibroblasts, and induces cellular differentiation. Additionally, the device will also be subject to one or more growth factors which may enhance differentiation of the cells.
“Our patent portfolio positions us at the forefront of human dermal fibroblast cell therapy for spinal disc regeneration,” said Pete O’Heeron, CEO of SpinalCyte. “As leaders in this field, we continue to expand our intellectual property protections.”
With this addition, SpinalCyte’s portfolio now includes 33 U.S. and foreign patents issued and 43 patents pending.
Based in Houston, Texas, SpinalCyte LLC is a regenerative medicine company developing a solution for spinal disc regeneration using human dermal fibroblasts. Funded entirely by angel investors, SpinalCyte represents the next generation of medical advancement in cell therapy.
The technology described in the patent involves an in vivo bioreactor that acts as a delivery system to feed and grow cells, like fibroblasts, and induces cellular differentiation. Additionally, the device will also be subject to one or more growth factors which may enhance differentiation of the cells.
“Our patent portfolio positions us at the forefront of human dermal fibroblast cell therapy for spinal disc regeneration,” said Pete O’Heeron, CEO of SpinalCyte. “As leaders in this field, we continue to expand our intellectual property protections.”
With this addition, SpinalCyte’s portfolio now includes 33 U.S. and foreign patents issued and 43 patents pending.
Based in Houston, Texas, SpinalCyte LLC is a regenerative medicine company developing a solution for spinal disc regeneration using human dermal fibroblasts. Funded entirely by angel investors, SpinalCyte represents the next generation of medical advancement in cell therapy.